BiotechTube
Home/Pipeline/BHV-2100 (mGluR2/3 NAM)

BHV-2100 (mGluR2/3 NAM)

Treatment-Resistant Depression (TRD)

Phase 1Completed

Key Facts

Indication
Treatment-Resistant Depression (TRD)
Phase
Phase 1
Status
Completed
Company
Biohaven

About Biohaven

Biohaven is a neuroscience-focused biopharmaceutical company with a diversified portfolio of clinical-stage and commercial assets. Following the spin-off of its migraine franchise to Pfizer in 2022, the 'New Biohaven' is advancing a next-generation pipeline targeting neurodegenerative diseases, movement disorders, and neuropsychiatric conditions. The company leverages multiple scientific platforms, including its proprietary glutamate modulation and myostatin inhibition technologies, to address complex neurological disorders with significant market potential.

View full company profile

Therapeutic Areas

NeurologyNeuropsychiatryNeuromuscularOncology

Other Treatment-Resistant Depression (TRD) Drugs

DrugCompanyPhase
SPN-820/821Supernus PharmaceuticalsPhase 2
PCN-101 (R-ketamine)atai Life SciencesPhase 2
VLS-01 (DMT)atai Life SciencesPhase 1
Salvianolic Acid Batai Life SciencesPreclinical
GH001GH ResearchPhase 2b
BMB-101Bright Minds BiosciencesPhase 2
MW-101MindWalk HoldingsPhase 2
NPH-101Neuphoria TherapeuticsPhase 1/2
CYC-126Cyclerion TherapeuticsPhase 2